


# ContraFect

## COMPANY OVERVIEW

ContraFect is a clinical-stage biotechnology company focused on discovering and developing biologic therapies for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our platform of direct lytic agents (DLAs), which include lysins and amurin peptides. We believe DLAs provide the opportunity to make meaningful improvements to clinical outcomes and to change the treatment paradigm for patients infected with antibiotic-resistant bacteria. Our initial product candidates are new agents to treat lethal, resistant infections such as methicillin-resistant *Staph aureus* (MRSA) and Gram-negative pathogens like multi-drug resistant (MDR) *Pseudomonas aeruginosa*.



## CONTRAFECT CORPORATION

28 Wells Avenue  
3rd Floor  
Yonkers, NY 10701  
US

## RECENT NEWS

### ContraFect Reports Third Quarter 2020 Financial Results and Provides Business Update

Nov 13 2020, 8:33 AM EST

### ContraFect Initiates Expanded Access to Exebacase for the Treatment of MRSA Bloodstream Infections in COVID-19 Patients

Oct 26 2020, 7:00 AM EDT

### ContraFect to Present at the 2020 Cantor Global Virtual Healthcare Conference

Sep 9 2020, 7:30 AM EDT

## STOCK OVERVIEW

Symbol	CFRX
Exchange	Nasdaq
Market Cap	163.25m
Last Price	\$5.87
52-Week Range	\$2.90 - \$13.399

11/25/2020 04:00 PM EST

## INVESTOR RELATIONS

Michael Messinger  
T: 914-207-2300  
[mmessinger@contrafect.com](mailto:mmessinger@contrafect.com)

## DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.

